- CH₣232.94bn
- CH₣265.12bn
- $56.33bn
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Swiss stocks - Factors to watch on March 27
Brief: Novartis Agrees To Acquire Excellergy, Inc.
China commerce minister meets pharma executives amid push for foreign investment
Deals of the day-Mergers and acquisitions
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Novartis to buy experimental breast cancer drug in up to $3 billion deal (updated)
Novartis to buy breast cancer drug candidate from Synnovation
Brief: Novartis Agrees To Acquire Pan-Mutant-Selective Pi3kα Inhibitor
Table: Swiss trade surplus at CHF 4.20 bln in February
Analysis: TrumpRx lists many medicines at prices higher than paid in UK
Big drugmakers must face US overcharge claims on medications for low-income patients
Europe Research Roundup: Basic-Fit, ENI, Neste
Julius Baer CEO tops highest pay at UBS
Brief: Novartis Board Of Directors Has Decided To Launch A New Share Buyback Program
Swiss stocks - Factors to watch on March 16
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research